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The Honorable Members of the California State Senate: 
We would like to call your attention to the attached report, 
Silicon Valley II: A Review of State Biotechnology Development 
Incentives, which was prepared by the Senate Office of Research. 
The report focuses on the intense competition that is developing 
between the states to attract and encourage the growth of the 
biotechnology industry. 
This exciting new industry has grown from nothing to over two 
hundred firms in less than ten years. Its continuing growth and 
prosperity is important to California for two reasons. First, 
promises new jobs for our growing workforce and economic develop-
ment for our cities. Secondly, advances in biotechnology will 
result in new products and processes that will improve health, 
increase productivity, and enhance living standards across the 
board. Biotechnology applications will affect virtually every 
sector of our economy as well, from agriculture to waste 
management. 
promise of this new industry, however, has not gone unnoticed 
state development officials around the country~ The attached 
report documents many of the very active steps tbat~ther states 
are takingyto promote the development of biotechnology within 
bord~rs, and demonstrates the increasing sophistication 
the economic development strategies that are being employed by 
those states. 
California is not in any imminent danger of losing % 
the biotechnology industry, state policy makers need to 
aware of its importance to California and the increasing com-
that we are facing. With this background in mind, we 
need to review the state's commitment of resources and 
to ensure that California will maintain its leadership 
tion in biotechnology. 
0 
f any questions about 
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The growing interest of other states in promoting the development 
of biotechnology has not escaped the notice of either state offi-
cials or private industry in Cali Increasing concerns of 
California legislators and private representatives about the 
growing competition and regulatory climate for biotechnology 
culminated in the passage in August, 1984, of Assembly Concurrent 
Resolution No.170. The measure was authored by Assemblyman Sam 
Farr with Assemblyman Robert Naylor as principal coauthor. Sena-
tors David Roberti and Rose Ann Vuich were Senate coauthors. 
ACR 170 called for two studies, specifically requesting: 
1. "the Assembly Office of Research to conduct a study, to be 
completed by April 15, 1985, reviewing all existing, pending, 
and elapsed federal and state regulations affecting the Cali-
fornia biotechnology industry"; and 
2. "that the Assemb ce of Research and the Senate Office 
of Research also study incentives being offered by other 
states and countries to promote .the development of biotech-
nology industry thin those states and countries." 
The first request was met with the publication of Review of 
Federal and State Regulations Affecting the California Biotech-
nology Industry, by James W. Rote, Assembly Office of Research, 
April 1985. 
This report is in response to the second study request. A draft 
version was distributed to members of the Advisory Committee 
es lished pursuant to ACR 170, to Lieutenant Governor Leo 
McCarthy's c Development sion, the California Eco-
nomic Development Corporation, other interested parties. The 
final version bene tted considerably from the comments received 
members of these groups. The author wishes to 
ir contribu , especially those from Norman 
and Nan Newell of Calgene, Assemblyman Sam Farr, Peter 
Staple of Cetus Corporation, an Cunningham of Genetech, Inc., 
and James W. Rote of the Assembly Office of Research. Any re-
maining errors and shortcomings in the report remain the 
responsibility of the author. 
SILICON VALLEY II: 
A REVIEW OF STATE BIOTECHNOLOGY DEVELOPMENT INCENTIVES 
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John Griffing 




During the last decade new discoveries and scientific develop-
ments involving recombinant DNA and cell fusion have given birth 
to a rapidly growing new industry called biotechnology. The 
number of newly established biotechnology firms now exceeds 200, 
and various estimates place 30-35% of them in California. 
Several other states across the country have shown keen interest 
in the development of biotechnology and have instituted a number 
of programs to attract expanding biotechnology firms. In 
addition, some states have taken major steps designed to "grow 
the industry" rather than just entice a few plant locations. 
These steps include expanding state support for biotechnology 
research and development at state universities as well as in 
private firms, increased state funding for university biotech-
nology education and training programs, and the establishment of 
state programs to provide financial and technical assistance to 
biotechnology firms. 
States with the most ambitious biotechnology programs -- such as 
North Carolina and New Jersey -- have also created biotechnology 
centers which offer a wide variety of incentives and assistance 
to biotechnology firms. In addition to the above noted programs, 
these centers provide the industry with improved access to uni-
versity research and technology, technical and financial assis-
tance, and incubator space and facilities. In some states the 
centers are operated by universities; in others, they operate as 
nonpro t institutions separate from any single university. In 
all cases, the centers strive to link the resources and research 
of universities to the needs of private industry. In addition, 
they emphasize interdisciplinary, intercampus research. Funding 
is typically provided through state, federal, and private indus-
try sources. 
The strategies that individual states are applying pursuit 
of biotechnology are a good deal more sophisticated and better 
funded than past state economic development strategies. While it 
is too early to evaluate the effectiveness of the various state 
efforts, the degree of sophistication, the levels of funding, and 
the fact that many feature public-private cooperation with sub-
stantial sums of private financing all suggest that these states 
will be successful in attracting biotechnology firms to and fos-
tering the development of new biotechnology firms within their 
borders. 
There are several reasons why the State of California may want to 
respond to the competitive challenge from other states. First, 
California is likely to lose plant expansions, new firms, and 
employment to other states unless it responds adequately. 
Secondly, the industry is in need of additional research and 
development, education and training, and other services of which 
state government is the principal provider. Third, advances in 
biotechnology will bestow an enormous range of benefits to 
society in agriculture, health, forestry, fisheries, pollution 
control and hazardous waste management, all of which are very 
important to the State of California. 
The options open to the State to assist the industry are rela-
tively straight forward: (1) increase biotechnology R&D; 
(2) expand education and training in fields related to biotech-
nology; and (3) establish programs to help the industry meet 
regulatory requirements and to increase public awareness of the 
nature of and benefits to the biotechnology industry. A summary 







Biotechnology, broadly defined, includes any technique 
that uses living organisms {or parts of organisms) to 
make or modify products, to improve plants or animals, 
or to develop microorganisms for specific uses. 1 
Background 
While biological processes and organisms have been used for cen-
turies, for example in baking, brewing, and farming, scientific 
breakthroughs in the last decade have revolutionized the field. 
New discoveries and developments in biotechnology, including 
recombinant DNA, cell fusion, and novel bioprocessing techniques, 
offer limitless potential for new and improved products, new 
processes for industry, and indeed, whole new industries. The 
new biotechnology may, in fact, be the most significant tech-
nological revolution of this century when judged in terms of its 
potential impact. 
The range of industries which will be affected by new biotech-
nology products and processes is staggering. The first and most 
important area is medicine where the production of insulin, 
feron, monoclonal antibody diagnostics, and various vaccines 
hold tremendous promise. In agriculture, researchers are engi-
new crop species which will be resistant to stress, 
he s, and pesticides and will grow more rapidly. New 
micro-organisms are being developed to inhibit frost formation to 
reduce frost damage to plants. New organisms and techniques will 
to enhanced oil recovery, help control pollution, degrade 
tox waste, and bring other environmental benefits. The chemi-
cal industry and food additives will be affected by the new 
biotechnology. So will electronics with the potential develop-
ment of biosensors and biochips -- devices that would act as 
semiconductors using protein molecules. 
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Many of the promising applications of biotechnology, such as 
biochips, will not be realized for years, possibly decades. 
Nonetheless, the potential benefits are overwhelming and a new 
industry is rapidly emerging. Beginning in the mid-1970s, entre-
preneurs from the scientific community began to establish new 
firms to capitalize on the breakthroughs in biotechnology. The 
pace of commercialization was particularly rapid in the United 
States, where in less than ten years more than 200 new biotech-
nology firms were established.* 
The initial spurt of growth in the biotechnology industry has not 
yet yielded much in the way of job creation, production, or other 
economic development. Nonetheless, it has caught the attention 
of an increasing number of state economic development officials, 
governors, and legislatures. One reason for this attention is 
that the initial public offerings by two biotechnology firms set 
Wall Street records and received widespread publicity. Genen-
tech's initial offering in 1980 set a record for the fastest rate 
of increase in the price of stock (from $35 to $89 in twenty 
minutes). In 1981, Cetus raised $115 million on Wall Street, a 
record for initial public offerings at that time. 
A second reason for the increased interest of state officials was 
that the emergence of biotechnology as a potentially large new 
industry coincided with the rapid growth of new state initiatives 
*Various estimates show California with approximately 35% of 
these firms. 
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to promote, develop, and attract high technology businesses. 
r to 1980, only four states -- Massachusetts, North Carolina, 
Connecticut and Florida -- had programs for the development of 
science and technology-based industry. Today, at least 33 states 
have programs aimed at developing high technology industry. Five 
of the remaining 17 states are launching high technology develop-
ment programs, and several others are in the planning stage. 2 
The rapid growth of state programs targeted at high technology 
industry can be explained by a number of factors. The tremendous 
growth of the electronics and computer industries in California 
and Massachusetts produced countless economic benefits for those 
states which, in turn, prompted economic development officials in 
many of the other states to try to duplicate that success within 
their own states. Another factor was economic hard times. Fol-
lowing the extended recovery from 1975-1979, the U.S. economy 
went through a series of ups and downs culminating in the 1982-83 
recession, the most severe recession that the u.s. has experi-
enced since the 1930s. On top of these short-term swings, the 
U.S. economy was (and may still be) undergoing a secular decline 
in the importance and strength of many of its basic industries, 
including autos, steel, and rubber, primarily as the result of 
increasing international competition. The tremendous declines in 
employment that occurred, particularly in the industrial heart-
land, state of ls to adopt or modify their economic 
development s s in to pursue new industry and jobs 
to replace the losses. 
A third factor involves the development of federal initiatives to 
stimulate state programs. In 1979-80, for example, the U.S. 
Department of Commerce offered several million dollars in match-
ing grants to state programs set up to provide financial assis-
tance to firms engaged in developing innovative technologies. 





The new state programs targeted at technology were, at least 
initially, outgrowths of traditional economic development pro-
grams. As such, the emphasis was on business firms to 
expand or locate new facilities in states. In other words, 
the early strategies were real marketing programs. le Cali-
fornia did very little marketing at time, saw plenty of 
evidence of the marketing efforts of other states. A number of 
them sent delegations -- some led by governors -- into Silicon 
Valley to entice California firms to expand or relocate their 
facilities in their states. 
During this period California lost a signi number of jobs 
and plant expansions (and some firms) to other states and coun-
tries. Some of those losses were widely and prominently adver-
sed, such as Dow 1 petrochemical 1 in Solano 
County and the transfer of by Atari to Taiwan. 
Despite these ses, has continued to generate new 
firms and jobs at a c that consistently outpaced the rest 
of the country for the past decade. 
A number of reasons have been offe 
continued economic success, 
technology sectors: {1) the excel 
to expla California's 
larly the success of s high 




c and , and the and qual 
an 
that has fostered risk-taking and has 
encouraged entrepreneurs to move new products and processes out 
of the research s; (3) abil of the state to attract 
of 
labor, particularly skil workers and scienti and engineer-
ing personnel; and, (4) the availability of financing for new and 
expanding firms, primarily the form of venture capital. 
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i 1 targeted to biotech-
incentive programs. 
contacts helped flesh out 
, and other aspects of the 
These surveys a useful starting point, but all suffered 
from a common limitation -- that of sorting out state biotech-
nology initiat from those designed to promote economic devel-
opment in general or even those more narrowly targeted to the 
development of technology. A decision was made not to 
restrict the study to just those programs that have been estab-
lished to foster the development of biotechnology. Such an 
approach would be too narrow in scope and would pass over a num-
ber of programs that have been initiated by states to foster the 
lopment of all or any new s based on science and 
technology. the , however, made it more diffi-
cult to 
tiat s to 
appropriateness and importance of specific 
logy. 
reason the r scope of this study is the lack of 
good formation on new programs, which biotechnology incentives 
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ment (OTA) and published in 1984. That report identified ten 
factors of potential importance in the international competitive-
ness of biotechnology. The ten factors in rough order of impor-
tance are: 5 
• financing and tax incentives for firms 
• government funding for basic and applied research 
• personnel availability and training 
• health, safety, and environmental regulation 
• intellectual property law 
• university/industry relationships 
• antitrust law 
• international technology transfer, investment and trade 
• targeting policies in biotechnology 
• public perception 
This list of factors served as the starting point for categor-
izing state biotechnology incentives for this chapter. Three 
adjustments to the list were subsequently made. First, the fac-
tors important solely to international comparison were elimin-
ated. The primary purpose of the OTA study was to analyze the 
international competitiveness of biotechnology in the U.S. versus 
Japan, West Germany, the United Kingdom, Switzerland, and France. 
Hence, trade, technology transfer, and antitrust policies were 
important in the OTA analysis. These policies, however, tend to 
be national, varying from country to country, but essentially 
uniform across subnational jurisdictions such as states. 
A second modification to the OTA list was the elimination of the 
regulatory category since this was the subject of a separate 
study requested by Assembly Concurrent Resolution 170. A final 
adjustment was made to accommodate novel categories of incentives 
that states are offering. 
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The resulting list contained the following six categories of 
incentives, around which Chapter II is organized: 
• Financial assistance -- direct 
• Financial assistance -- indirect 
• Information and technical assistance services 
• Research and development 
• Education and training 
• Technology centers 
As the reader will no doubt discover, the list is still somewhat 
arbitrary, and the categories are not necessarily mutually-exclu-
sive. Moreover, some state programs could be listed under one or 
more of the categories. In fact, some state programs are multi-
purpose and thereby fall into several of the categories. An 
effort was made to avoid double counting by sorting the programs 
on the basis of their primary function and listing them only 
once. Most of the multipurpose programs are described under the 
final category, technology centers. 
CHAPTER II: 
STATE BIOTECHNOLOGY INCENTIVES 

CHAPTER II: 
STATE BIOTECHNOLOGY INCENTIVES 
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s invested in 27 cornpanies. 3 
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More traditional loan programs targeted to high technology firms 
have also been started in several states as a result of a pilot 
federal program in the late 1970s and early 1980s. Included in 
this category are the California Innovation Development Loan 
Program, the Connecticut Innovation Development Loan Fund, and 
the Corporation for Innovation Development in New York. These 
programs are evidence of the shift in development strategies that 
has occurred; their objective is to foster the development of new 
technology through loans to relatively young firms, rather than 
simply providing loans to the more traditional business recipi-
ents. The programs, however, have been hampered by a lack of 
funding -- initial capitalization for each corporation was only 
$1 to $2 million. 
Financial Assistance -- Indirect 
The lack of adequate funding for the innovation development loan 
programs is symptomatic of the reluctance of state governments to 
provide direct financial assistance to business firms. States 
have been less hesitant to offer indirect financial assistance, 
especially through tax incentives, which leave the actual financ-
ing decisions in the hands of private investors. 
Since nearly every state offers one kind of tax incentive or 
another for business expansion, it would be difficult and of 
little use to catalogue those incentives here. Three recent tax 
incentives targeted to the development of high technology compa-
nies are, however, noteworthy. The State of Indiana allows a tax 
credit of 30% on individual investments in a venture capital pool 
that is administered by a state-chartered, privately-owned, non-
profit Corporation for Innovation Development. The pool is pri-
vately funded with no state contributions. 4 Minnesota recently 
enacted a tax credit of 30% of the value of the technology trans-
fer that occurs when a small business is spun off from a parent 
stments 
more 
Senator Pre took e 
ts s tax 
s 198 
1 source of 
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contributions private Most centers also actively 
recruit federal funds research ects, facilities, equip-
ment, and other programs of 
Billed as 
the North Caro 
centers. 
in biotechnology, 
Center (NCBC) is clearly the 
flagship of state technology centers. NCBC was founded in 1981 
by state as a nonpro corporation to encourage 
and facilitate c 
, industry, venture 
among researchers, universi-
government. It is 




neering, and NCBC's goals ectives are to: 
• Stimulate 
and education programs in 
nology. 
iplinary research 







sing new research and 
it s and small business. 
• Facilitate mutual 
t s and indus 
1 col between universi-
• Promote lopment of new and sting companies in North 
Carolina 1 s among reneurs, industry, sci-
entists, 1 i , and state and local economic 
development groups. 
• Improve the understanding of biotechnology among all sectors 
of North Carolina society. 
The 1 t of programs and activit s that are sponsored by the 
center is a one and 
publications, workshops 
s: a newsletter and various 
conferences, a visiting scholars 
program ch places al scientists and engineers in fac-












, and the Monoclonal 
Center. state currently provides 
center's budget. Industry funding 
ject sis and to date has amounted 
same as state funding. center also recruits 
NSF, NIH, and sources. It is cur-
th the U.S. Navy on a $675,000, three-year 
b mate als. NCBC is not doing 
itself, 
s 
stment of $70 
the subcontracts and handl-
s no overhead. 
Study Commission of the 
of North Carolina recently rec-
11 in additional funds for 
CHAPTER II. -2 
a comprehens to 
in 
$24 million to NCBC to help the economic impact of 
biotechnology development biotechnology research, to 
throughout the state, to s research grant pro-
gram. 
• $1.12 to the NCBC to construction of a new 
facility to carry out responsibilities. Addi-
tional funds are to be sought from public and private 
sources. 23 
The State of New Jersey has 
lels North Carol 's 
a biotechnology program that 
scope and magnitude. The New Jer-
sey plan, as with several states, stems from the work of a 
state task force, in this case Governor's Commission on Sci-
ence and Technology. This san, blue-ribbon panel of 
industry government o 
tember 1982 and concluded 
mission studied 
ined the role and 
several 
first meeting in Sep-
s activities in June 1984. The Com-
of the New Jersey economy, exam-
technology industry, appointed 
more ly specific topics, 
and final developed a set of recommendations -- unanimously 
supported ss -- regarding the future opportuni-
for job d ' 24 eve 1n New Jersey. 
cornerstone of s recommendations was a 
$90 llion act was enacted the Legislature and 
I . -29-
, 1984. Key features of 
the 
state's voters 
25 act are: 
• $42 11 for the es lishment and construction of a net-
centers at the state's public and of advanced 
private titutions of higher education which may include, 
but are not limited to centers in biotechnology, food science, 
hazardous and taxies substance management, and industrial 
ceramics; 
• $15 million for advanced technology centers in areas of future 
economic development;* 
• $23 million for the construction and improvement of undergrad-
uate technology and engineering facil ies and equipment for 
h r technology job training retraining programs to be 
among the county col , private higher 
pub h r education institutions; 
• $10 of Higher Edu-
community col-ca 
ssage, four bil s were introduced in the 
slat to enact specific provisions of the 
Act. One of lls, Senate 11 1654, establishes the 
s Techno to replace the 
ss had red. new commis-
s is of, operate independently of, the New 
* Bond Act speci that establishment of an advanced 
technology center shall include a commitment from industry to 
finance a of the center's operating costs. 
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s at academic itutions 
and other can advance economic development 
and employment; 
to encourage and 
and inventors. 
A second bi , As 
of Advanced 







to help entrepreneurs 
s for the establishment 
(ATCB) • Both 
houses of the New 




AB 1764 is to j governed by 
are to 
functions of center 
1. to establish to 
industr ; 
2. to support 
ensure that all sectors 







biotechnology research and 
logy and 













il s available to 
logy; 
ces to bus ss engaged 
s: and 
to the New Jersey Commission on Sci-
(as provided for in AB 1654) concerning 
* 
$20 million from the $90 million 
bond issue and an additional $20 million from Rutgers University 
and the Universi of Medicine and Dentistry of New Jersey under 
an independent bond issue. The money will help construct new 
facili s and 
itut For 




















existing resources at other research 
1985, the Governor's Commission on 
$1.2 1 operating funds for 
1 $600,000 11 go the innovation 
centers North Caro and New 
e , a number of other 
, if more modest, programs. These 
and Virginia. Their programs 
low. 
Techno Foundation, the 
several centers for advanced 
ltural 
rs of New 
The Cornell 
biotechnology, and the center 
at Stony Brook emphasizes 
rship grants are defined 
researchers performing applied 
es at the state's public and 







are ointly funded by 
Cornell center receives 
Te logy Foundation, 
and so far has have signed six-
contracts totalling $2.5 1 each. The medical biotech-
nology center at Stony Brook has 11 corporate sponsors. The 
programs promote research productivity by concentrating re-
searchers in one lding, so he s reduce costs by 
allowing expensive equipment to shared, and they stress inter-
disciplinary research. Program funds are to be used for faculty 
research grants, recruiting lty and setting up labs, central-
ized research facilities and specia , educational programs 
for faculty and industry, industry-faculty exchange, and services 
and facilities to foster 
. 30 compan1es. 
establishment of small biotechnology 
Virginia -- The Commonwealth of Virginia has established a Center 
for Innovative Technology to promote research, to foster 
industry-university cooperation, and to serve as a broker between 
industry and univers research needs and ongoing 







technologies, not just 
Maryland -- e 
ity research and develop-
! research institutions -- the 
rginia Commonwealth 
research and development in all 
logy.31 
ished a Biotechnology Institute at 
the Univers of Maryland will serve as an umbrella organ-
ization for a Center Advanced Research in Biotechnology. The 
center is being set as a co effort between the 
university, industry and state, local, and federal governments 
to focus on biomedi biology, and agricultural applica-
tions. The center, which current design phase, will 
I -33-
re 
Standa , and 
ventures. 32 
cil s, a 
tor facil 
to the National Bureau of 
s new logy 
Three conclusions emerge from the review of the incentives and 
other programs that states are providing in their efforts to 
attract and promote biotechnology. 
(1) A number of states are aggressively pursuing the new indus-
try in order to attract firms, to encourage the development 
( 2) 
(3 
of new , and to foster the diffusion of new biotech-
nology products and sses within their states. 
The s s states are applying in the pursuit of 
biotechnology are a good deal more sophisticated and better 
funded 
1 more 0 
to 
states. 
It is too ear to eva 
deve 
new 
strategies, which have 
efforts designed to 
faci s in their 
the effectiveness of these bio-
efforts by the states. A number of the incentive 
are actual sals, others are still in 
s The o st are only three to 
four 
fact many 
stantial sums of private 
these states will 
no logy 
techno 
rms to fos 
less, 
f 
the degree of sophistication 
levels of funding, and the 
-private cooperation with sub-
corporate financing all suggest 
successful attracting biotech-




OPTIONS FOR CALIFORNIA 

CHAPTER III: 
OPTIONS FOR CALIFORNIA 
At-a-Glance Options for Promoting Biotechnology 
A. Provide Financial Assistance to Biotechnology Firms 
B. Help Expand Biotechnology R&D Activity 
1. R&D Tax Credit 
2. Direct State Expenditures 
a. University R&D 
b. Matching Grant Program 
c. Grants to Small R&D Firms 
c. Increase Education and Training Funding 
D. Provide Technical Assistance and Information 
1. Public Education 
2. Regulatory Assistance 
E. Establish One or More Biotechnology Centers 
Should the State of California Respond? 
One school of thought argues that the best thing that state 
government, indeed all government, can do is to stay out of the 
way the industry operate and prosper without any inter-
or assistance. Proponents of this view often cite the 
success of Ca i a's electronics and computer industries as 
high technology industry can flourish without gov-
ernment. 
s view is, of course, oversimplified and glosses over the role 
government has played in the development of high technology 
industries in this country. The federal government, and to a 








fornia expects to maintain s 
likely that it 11 to se 
Otherwise, it is likely to lose p 
employment to other states. 
A second reason the State should cons 
biotechnology industry is current in 
responding is 
of additional 
research and development, education and training, and other 
services of which state government is one of the principal pro-
viders. A third reason is independent of the potential job 
development benefits that biotechnology holds in store. 
Biotechnology wil be one of, if not techno 
next two or three decades, and will stow an enormous range 
of bene s to soc lture, stry, 
fisheries, pollut control, hazardous waste management, all 
of which are very important to the State of California. 
* Government regu policies have also o been a s fi-
cant factor in in ing industrial lopment. 
are opposed to government assistance for biotechnology deve 
opment are typically in favor of ss regulation as well. 
Since it is the subject of a separate report, recommendations 
regarding regulatory policy will not be 1 
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State Options for Promoting Biotechnology 
A. Provide Financial Assistance 
Although a number of states have embarked upon programs to help 
provide financial capital for high technology startups and expan-
sions, there is at this point in time no such identified need in 
California. As noted earlier, California leads the country in 
raising and committing venture capital, which is one reason that 
the biotechnology industry has flourished in this State. A sec-
ond argument against providing public capital is that the State 
is probably not a better judge than private markets of the risks 
and benefits of biotechnology investments. Although some state 
programs have been successfully implemented, they are relatively 
small and unlikely to have much of an impact, if any, on the 
development of the overall industry. 
B. Help Expand Biotechnology R&D Activity 
Rather than provide financial assistance, the State could help 
fund additional research and development either through an R&D 
tax credit or through direct appropriations. This option would 
not only address an identified need of the biotechnology indus-
try, it would help them to meet indirectly their needs for finan-
c 1 capital. The need for additional R&D has been articulated 
OTA study2 , in the incentives that other states are pro-
viding, in hearings before the California Assembly Committee on 
Economic Development and New Technologies 3 , and in meetings of 
the ta force established pursuant to Assembly Concurrent Reso-
lution 170 4 . Given the importance of stimulating additional R&D, 
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• Scope of coverage is also a problem with the simple R&D tax 
t. A substantial portion of R&D expenditures is directed 
at product and package design and other marketing type goals. 
There are no justifiable economic grounds for subsidizing such 
activity, yet it is not clear how an R&D tax credit can be 
designed to exclude those activities. 
• Another drawback to a straightforward tax credit for R&D 
expenses is the potential revenue loss to the State. Accord-
ing to estimates by the U.S. Treasury Department, the federal 
revenue loss from the 25% incremental federal tax credit is 
$700 million per year. If a similar credit were enacted in 
California, at say a rate of 10% rather than the federal 25% 
rate, it would reduce California's franchise tax and personal 
income tax by some $35 to $50 million per year, according to 
some estimates. 
An alternative to the simple tax credit would be to grant tax 
credits to private firms for contributions to specified R&D cen-
ters, including but probably not limited to biotechnology cen-
ters. University-based research foundations would be the most 
likely recipients of such contributions, but eligibility could be 
extended to cover nonprofit industry research centers as well. 
This type of tax credit nevertheless faces similar difficulties 
as tax credit based on in-house research. Dilution of state 
incentive due to the federal tax code remains a severe obstacle. 
The problem of defining acceptable R&D remains to some degree and 
might be complicated by requiring a list of acceptable institu-
tions to receive corporate donations, as well as designating what 
ions can be used for. 
2. rect State Expenditures 
D state expenditures for basic and applied research is the 
only general alternative to state tax credits as a method of 
stimulating biotechnology R&D. Direct support can be provided in 
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, with on 
is greater tar-
f c bureaucracy. Review 
greater staff being required as 
o the program grows. A program 
st staff if done rela-
the eligibili being determined 
s loses the priori setting, however). 
a of advantages over the tax 
• By providing 
young firms not 
r to nonpro t institutions or to 
lities, it would guaran~ee 




more research and deve4~~ .... ~ 
federal government. 
wou lude 
of R&D suitable 
could 
need to develop a rigorous 
all firms. 
istered to reflect changing 
could determined in advance 
depending on the uncertain R&D 
to se appropriate R&D 
guided by a statutory definition 
uenc 
of state 
create an excellent opportu-
ss and other constit-
formulating economic policy. 
s as well: 
ities may absorb more of 
poorly directed activities 
creates potential complica-
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s not as 
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ts 11 ss 
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s 
to the s 1 
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requirements. On the other hand, 
s are re 
biotechnology 
mature 
They are all 
and marketing products, and several have reached the 
f 500 st strial firms in the u.s. As 
a result, 
outs re 
been a much 
when compared with 
pos ion to finance 
biotechnology industry. 
The latter, of course, is 11 comprised of firms that are in 
the pre stage and are surviving on infusions of capi-
tal from venture 1 or other sources. This situation 
sts the MICRO program model may be premature for the 




has sprung forth from the univer-
nurtured 
programs, although 
1 as the 
the university-
s needs for the 
moves into 
fu 1-scale co~merc lization. s from the industry 
personnel for 






lity of skilled 
and ring talent needed 
needed for production. The OTA 
for additional training and educa-
to biotechnology has 
ss to c in such a program 
the fie patent and licensing poli-
to a program according to at least 
commentator. 
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State of Cali to 
I ld careful 
related education and do so is 
s c is state 
elects to do to 
expand biotechnology 
additional R&D. Programs des 
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training programs. In other s, the state can size one 
or the other function, depending upon the lar needs of the 
state's universities biotechnology , but should not 
exclude 
One way in which the State 
technology industry, and 
intern program 
plines (such as chemis 





to es sh an 
related sci-
, etc.) wou be 
logy 
s and wou ck 
s. The State 





D. Provide Technical Assistance and In 
The California of Commerce, 1 s 
other states, is responsib ion 
nical assistance and per various other ions to 
mote and assist the bus ss community. Department's mandate 
out 
State, and the 
to 
to 
ial assistance, but the 
tries, 
ts to the State. 
new 
program is a 
expanding 
An informational brochure has 
logy firms in the 
is prepared to offer its excellent site 
selection assistance to interested 
Two addit 1 areas of assistance public education and regu-














i as lly useful expan-
representatives in meetings of 
and in comments received on the draft 
a i a to educate 
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awareness wou he foster a bet-
of biotechno industry in Cali-
environment) 
State to 1 support for 
lar incent s. 
o s sort, while unusual, is not 
Cali government. The Depart-
of sm is dedicated to promoting a 
state industry. To some extent the 
Food Agriculture and the California 
respective "indus-
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re ibility) could 
regu scus-
could also act as an advo-
regu issues important to 
cance o biotechnology indus-
would a natural ro for the 
Governor and of Commerce to assume. 
issue was raised by several members 
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development programs of states 11, ss California 
s success l Cali for-
n 's share of 
This is not to cone that State is imminent danger of 
losing the Ca currently approximate 35% 
of the biotechnology firms have been estab shed the last 
decade. Furthermore, excellence of state's rsi 
the availabi of , and a entrepreneurial 
climate should keep the in re ly good shape. None-
theless, as the biotechnology revo ion moves the R&D labs 
into full-scale production, Ca fornia's comparative advantage at 
incubating new firms diminishes in importance. New production 
facilities are apt to be spun off to locations following 
the pattern of the electronics computer industries. To 
counter those losses, the State needs to ensure that it retains 
its share and that new products, new , and new jobs continue 
to be developed. 
Keeping California's will not be as easy as it 
once was. Other states from the past successes of 
Silicon Valley and Route 128 outside Boston, and they are devel-
oping biotechnology are a deal more s-
ticated. These are now not on at 
s plans of Ca , at 
past successes -- s universities, its education 
and training programs, R&D capabil 
The options for the State of California are relatively straight-
forward: (1) increase biotechnology {2) expand education 
and training in fie re to biotechno and (3) assist 
the industry to meet regu rements and publ 
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AsS<.·mbly Con<·urrcnt Ucsolution No. 170 
HESOUJTIO:'\ CHAPTER 130 
Asst•mhly O:mC'urn•nt Hc.-solution 1\o. l7U--Hdativc> to biotl'Ch· 
nology. 
IFilt'<l with ~'<'rt'lary nl Stall' .\111£11'1 :11. 1~.1 
I.E< :lSI AT I\ E ( :( )l ''SEI :s I> I< ;t·~\T 
ACH 170. F<~rr. Hioh'!'hnology. 
This mc>asurc> rc>qu«•sts the> Assl•mbly Offic<' of R<•sc>arch to conduct 
a study, to be> complt'll'd by April 15. 19H5, f<'Vi<'wing ull <'Xisting. 
p<•nding. ;llld <'lapsc>d f(•d<'rul ;mel stat(' rl'gul;.ations am.•cting th<· 
( :alifornia biolPchnology industry so th<~t th<' Lc-gisluhm• can muk<' 
infornwd cl<'cisions on hf}\\' to promote> th<' hiot<'Chnologr industry 
whil<• proh.•cting public h<';.alth and s;.afc>ty and th<' l'll\'ironm<'nt. 
WIIEHEAS. California is tlw int<'ll<•chml cc>nt<'r of th<' nation\ 
biukdmology industry: unci 
WIIEHE:\S. Approximat<'ly 35o/(' uf llw nation's biol<'chnology 
c·ompanil's, induding tlw IC'ading comp;.mi<'s. t.tr<' h<'adqmart<'rro in 
( :alifornh1: and 
WI IERK\S, Californiu c:umpanil'S han· air<'<tCiy d<'\·dopl'<l 
products. such ;1s human insulin and proinsulin, und int<'rf~ron. 
which han• tlw potential to alll•viatc hummt suff<'ring and illn<'Ss; and 
\\'II ERE:\S. Biot<'<·hnological r<'sC'arch is \'ita I to Californiu 's 
agricultural industry, offt•ring prosp('('ts of incn•as<'d production. 
,.a<.·dm•s for anim;~l disc.•as<'s, dis<'aS<' rC'sistant food crops. drought 
rPsist.mt plant strains. <llld mor<' nutritional foodstuffs: &Uld 
\\'IIERE:\.S. Th<' llnit<.•d Stt.~l('s P;lt<'nl ilncl Trad<'nwrk Offi<·<' has 
rt'('l'in•d in rPC('Ill Y<'<~rs IW<trl~· one> thous.md pat<'nl applications 
bHsPd on biotC'chnological n's<'arch: ;,mel 
WI IEREAS. Tlw bioh•dmology fidd is Ji!rowin~ mor<' cnmJwtitiw. 
particular!~· with r<'sp<'Ct to Pacific Rim ;.mel Europ<'<m countri<•s 
<~ccording to tlw Congrc.•ssional OITicC' of Tl'Chnology 
Assc.•ssnwnt. prh·att.• und public compuni<'s som<'timcs be-nefit from 
gnn•num•nl subsidi<'s: uml 
WIIEHK\S. Tht> St:ah' of C;llilcmJia should t>xplon• appropriat<' 
nwthods of assisting tlw stah··s biott'Chnology industr~·: .mel 
\\'IIERE.\S. 'umc>rous fC'dNal and statC' <tgl'llci<'s. including thC' 
'atiunallnstitutc>s of llt••alth and Envirmum•ntal Proh'Ction :\~Pncy. 
tlw Statt• Dt•partm<'nt of Food and :\grkulhm•. and the Stat<' 
Dt•p;trhllt'llt of Ul'<llth St•n·ict•s. <ldminish•r c.•n\'ironm<'ntal and 
lwallh rc>gulations afl<-cting biotl•chnology r<'st•arch ;md applications: . 
and 
\\'IIEHE:\S. Tht•st' r<'~ulations han• succc>ssfully prolt't't<•d without 
incidt•nt the public ·s h<'alt h and saft•ty and the <'m·ironment during 
'l'i Iii I 
~~'""f"r"''"'""'"t its 
acting on mutters 
biotechnology 
